Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis (RAVE)
This study is ongoing, but not recruiting participants.
Study NCT00104299 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: February 24, 2005 Last Updated: May 13, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Vasculitis
Wegener Granulomatosis
More general conditions related to this trial
Cardiovascular Diseases
Kidney Diseases
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases
Urologic Diseases
Vascular Diseases
Interventions listed in this trial
Rituximab
Cyclophosphamide
Azathioprine
Prednisone
Additional drug interventions recognized in this trial
Glucocorticoids
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
More general drug interventions related to this trial
Alkylating Agents
Anti-Inflammatory Agents
Antiemetics
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network
Back to top of Main Content
